


5. Ausschreibung Gesundheit im 7. EU-Rahmenprogramm

Dr. Ylva Huber
FFG – Europäische & Internationale Programme

Die Struktur der FFG – Österreichische Forschungsförderungsgesellschaft mbH



Dr. Astrid Hoebertz
Nationale Kontaktstelle Gesundheit => **HEALTH FP7**
05 7755 4104
astrid.hoebertz@ffg.at



Dr. Ylva Huber
(Stellv.) Referatsleiterin
Expertin Gesundheit => **IMI**
05 7755 4102
ylva.huber@ffg.at



Dr. Ines Haberl
„SMEs go Health“ Koordination
Nationale Kontaktstelle KMU
05 7755 4103
ines.haberl@ffg.at



Elke Wenzl
Assistenz
05 7755 4111
elke.wenzl@ffg.at

Seite 3

Das 7. EU-Rahmenprogramm (RP7):

- Größtes, internationales, kompetitives, kooperatives F&E Programm
- Unterstützung der Wettbewerbsfähigkeit Europas
- ab dem RP7: 7-jähriges Programm
- Strategisches Programm, thematische Vorgaben
- Budget: 54 Mrd. Euro

Seite 4

Struktur und Budget RP7



Seite 5

1. Spezifisches Programm: Kooperation



COOPERATION – Collaborative research
Vordefinierte Themen und "Instrumente"

1. Gesundheit	6,1 Mrd €
2. Lebensmittel, Landwirtschaft, Fischerei, und Biotechnologie	1,9 Mrd €
3. Informations und Kommunikationstechnologien	9,0 Mrd €
4. Nano, Werkstoffe und Produktionstechnologien	3,4 Mrd €
5. Energie	2,3 Mrd €
6. Umwelt (einschliesslich Klimawandel)	1,9 Mrd €
7. Verkehr (einschliesslich Luftfahrt)	4,1 Mrd €
8. Sozial-, Wirtschafts- und Geisteswissenschaften	0,6 Mrd €
9. Weltraum	1,4 Mrd €
10. Sicherheit	1,4 Mrd €

Seite 6

RP7 Thema 1: Gesundheit (6,1 Mrd. Euro)



Ziele:

- Verbesserung der Gesundheit der europäischen Bevölkerung
- Stärkung der europ. Industrie/Firmen im Bereich Gesundheit
- Blick auf globale Gesundheitsfragen (z.B. Epidemien)



Fokus:

- **Translationale Forschung** (*basic research* → *clinical application*)
- Neue **Therapien** (Entwicklung und Validierung)
- Diagnostische **Instrumente**, medizinische **Technologien**
- Effiziente **Gesundheitssysteme**

=> Im Thema Gesundheit unterstützt RP7 Grundlagen- und angewandte kollaborative Forschung – inkl. klinische Studien

Seite 7

RP7-Ausschreibungen zu Gesundheit im Überblick:



- 1x/Jahr wird von der EC eine Ausschreibung/Call in "Gesundheit" veröffentlicht
 1. Call - Einreichfrist: 19.4.2007; 637 Mio €
 2. Call - Einreichfrist: 18.9.2007; 549 Mio €
 3. Call - Einreichfrist: 3.12.2008; 591 Mio €
 4. Call – Einreichfristen zw. Okt 2009 – Feb 2010, 640 Mio €
 - 5. Call – voraussichtliche Veröffentlichung Ende Juli 2010**
- Ausgeschriebene Themen, Gesamtbudget etc. stehen in einem sogenannten "Arbeitsprogramm/Workprogramme"
- Themen/Topics sind exakt vorgegeben, ebenso Projekttyp und damit Projektbudget

Seite 8

RP7 Thema 1: Gesundheit - Struktur

1

Biotechnology, generic tools and technologies for human health

- 1.1 High-throughput research
- 1.2 Detection, Diagnosis and Monitoring
- 1.3 Suitability, Safety, Efficacy of Therapies,
- 1.4 Innovative Therapeutic Approaches and Interventions

2

Translating research for human health

- 2.1 Large Scale data gathering and Systems biology
- 2.2 Brain and Related diseases, Human development and Ageing
- 2.3 Translational research in major infectious diseases
- 2.4 Translational research in other major diseases (Cancer, CVD,)

3

Optimising the delivery of health care to European Citizens

- 3.1 Translating results of clinical research outcome into clinical practice..
- 3.2 Quality, Efficiency and Solidarity of Healthcare Systems
- 3.3 Enhanced Health promotion and disease prevention
- 3.4 International Public Health & Health Systems

4


Other Actions across the Health Theme

- 4.1 Coordination and Support actions across the theme
- 4.2 Responding to EU policy needs

Seite 9



The Health Theme Three main activities ("pillars")



cross-cutting issues: **international cooperation, SMEs, child health, ageing** populations, **gender-related** health issues

Activity 4: Support actions & response to policy needs



7. Rahmenprogramm

Cooperation

Theme 1: Health

- ↳ Pillar 2: Translating Research for Human Health
 - ↳ Area 2.4: Translational Research in other major diseases
 - ↳ Area 2.4.1: Cancer
 - ↳ Topic HEALTH.2011.2.4.1-2: Translational Research on cancers with poor prognosis

Seite 11

Beispiel Topictext

=> mit einem Projekt muss der gesamte Topictext abgedeckt werden

HEALTH.2011.2.4.1-2: Translational research on cancers with poor prognosis. FP7- HEALTH-2010-two-stage.

Collaborative research must either focus on stomach cancer, ovary cancer, brain cancer or multiple myeloma. The successful consortium will reverse-translate clinical observations concerning treatment failure into innovative cancer models closely mimicking the disease, while validating better therapeutic strategies that increase patient survival. Consortia must include clinical expertise to guarantee a clinical proof-of-principle. Active participation of research intensive SMEs could lead to an increased impact of the research proposed and this will be considered in the evaluation of the proposal.

Funding scheme: Collaborative Project (Small or medium-scale focused research project)

EC contribution per project: max EUR 3 000 000

One or more proposals can be selected.

Expected impact: The results of research in this area will have to contribute to ultimately reducing patient mortality for a number of difficult-to-treat cancers with dismal survival rates and integrate basic-clinical European scientific excellence.

Seite 12

Projekttypen (1)



Verbundprojekte – Collaborative projects – **klassische Forschungsprojekte**

- Ziel: neues Wissen, neue Produkte
- Forschung in unterschiedlich großen Konsortien – Größe abhängig vom Bereich und Forschungsgegenstand

1. **Small or medium-scale focused research project**

- Förderhöhe: maximal 3 Mio € (Medium: 6 Mio €) EC contribution / Projekt
- ø 10 Partner
- meist 3 - 4 Jahre Laufzeit

2. **Large-scale integrating project**

- Förderhöhe: maximal 12 Mio € EC contribution / Projekt
- ø 18 Partner
- meist 4 – 5 Jahre Laufzeit
- zwei Ausnahmen dieses Jahr: maximal 30 Mio € EC contribution / Projekt

Seite 13

Projekttypen (2)



Unterstützungs- und Koordinierungsmaßnahmen – **Supporting Actions and Coordinating Actions**

- Kombination oder einzelne Durchführung von Konferenzen, Studien, Analysen, Personalaustausch, Verbreitung von Ergebnissen, Netzwerkbildung... – keine Forschung!

1. **Coordinating Action**

- Förderhöhe: maximal 2 Mio € EC contribution / Projekt
- ø 12 Partner
- meist 3 - 4 Jahre Laufzeit

2. **Supporting Action**

- Förderhöhe: maximal 0.5 Mio € EC contribution / Projekt
- ø 6 Partner
- meist 2 – 3 Jahre Laufzeit

Seite 14

Wer kann teilnehmen?




Mitgliedsstaaten – EU 27

Assoziierte Länder - Associated Countries

- Island, Liechtenstein, Norwegen, Schweiz, Dänemark
- Türkei, Kroatien, Serbien, Mazedonien (FYROM), Albanien, Montenegro, Bosnien-Herzegowina

International Cooperation Partner Countries (ICPC)

- ACP Countries (African, Caribbean, Pacific)
- Asien (z.B. China, Indien, Iran...)
- EECA (Eastern Europe and Central Asia, z.B. Armenien, Georgien..)
- Lateinamerika
- MPC (Mediterranean Partner Countries, z.B. Ägypten, Algerien..)
- WBC (Western Balkan Countries => Kosovo)



Andere Third Countries: **USA**, Canada, Japan, etc.

Ausnahme Health !!!


Wer kann teilnehmen?



**Teilnahme steht jeder Rechtsperson offen,
wenn Mindestteilnahmebedingungen erfüllt sind:**

- Mindestens drei Rechtspersonen (RP) aus drei verschiedenen Mitgliedstaaten (MS) oder assoziierten Staaten (AS)
- Unterstützungsmaßnahmen: mind. 1 Rechtsperson
- Zusätzliche Anforderungen können in den Arbeitsprogrammen definiert werden, z. B. für SICA - Projekte (**S**pecific **I**nternational **C**ooperation **A**ctions)

Beispiel: Small collaborative project



Seite 17



Collaborative research

across borders and other barriers

- **between countries:**

- multinational consortia, with at least 3 partners from 27 EU Member States (**MS**) + 12 Associated Countries (**AC**)

- researchers from **any country in the world** can participate, from industrialised countries and from developing countries.

- **between different types of organizations**

- Public & private sector: universities, research centres, large companies, Small and medium-sized enterprises (SMEs), etc.

- **between disciplines:** multidisciplinary, translational research



Wichtige horizontale Aspekte für Gesundheit in RP7



Spezieller Fokus und Maßnahmen für:

- **KMU (Kleine und Mittlere Unternehmen) = SMEs**

- Teilnahme erwünscht in allen Bereichen
- Spezielle Topics für KMU
- Spezielle Unterstützungsmaßnahmen

⇒ Von den 6 Mrd € für das Thema Gesundheit sind mindestens 15% oder 900 Mio € für KMUs eingeplant

⇒ theoretisch sollte in jedem Projekt mind. 15% des “requested budget” an KMU gehen

5. Ausschreibung Gesundheit 2010



Focus on 5 Key Research Challenges

1. Increasing innovation and competitiveness of European health-related industries and services by attracting higher SME participation
2. Two pilot actions for high impact research initiatives
3. Supporting innovative clinical trials to verify safety and efficacy
4. How lifestyle affects health and how this can be mitigated
5. Global health issues

1st Key Research Challenge: SMEs



Increasing innovation and competitiveness of European health-related industries and services by attracting higher SME participation

- Research-intensive SMEs need to be attracted to participate to ensure that new R&D findings are brought to the market and to the bedside
- To boost SME participation, a number of specific topics are included with opportunities for SMEs not only to participate, but to take leading roles in projects
- To ensure a bottom-up and innovative approach, the topics are broadly defined and two-stage

Seite 21

1st Key Research Challenge: SMEs



HEALTH.2011.1.1-1: SME-targeted research for developing tools and technologies for high-throughput research. FP7-HEALTH-2011-two stage.

Funding scheme: SME-targeted Collaborative Project

EU contribution per project: Maximum EUR 6 000 000.

One or more proposals can be selected.

Additional eligibility criterion: SME-targeted Collaborative Projects will only be selected for funding on the condition that the estimated EU contribution going to SME(s) is 30-50% or more of the total estimated EU contribution for the project as a whole.

Seite 22

2nd Key Research Challenge: „HIPs“



FFG

Two pilot actions for high impact research initiatives (large-scale integrating research projects, up to €30m)

1. High Impact Initiative on the human Epigenome
2. High Impact Project for better immunisation

Seite 23

3rd Key Research Challenge: Clinical Trials



FFG

Supporting innovative clinical trials to verify safety and efficacy

- currently, majority of clinical trials performed by health-related industries during the development of novel products
 - clinical trials initiated by academic investigators are of high relevance for public health
- => several topics for clinical trials, most being investigator-driven clinical trials
- => strengthen clinical research in Europe in a number of areas with unmet medical needs

Seite 24

Clinical Trial topics

CT

Guiding principles:

- Broad topics (more bottom-up)
- Two-stage submission/evaluation
- Several proposals funded per topic
- Ceiling of €6m or €12m
- The scope will be specified in each topic, and the phases that can be covered will be largely governed by the budget
- Explanatory text in introduction of work programme
- 8 topics with a total indicative budget of €150-200m.



25

Clinical Trials Topics



- Regenerative medicine clinical trials
- Investigator-driven clinical trials for childhood-onset neurodegenerative diseases
- Investigator-driven clinical trials for therapeutic interventions in the elderly populations
- Investigator-driven clinical trials of off-patent antibiotics
- Investigator-driven treatment trials for rare cancers
- Investigator-driven clinical trials for the management of cardiovascular diseases
- Investigator-driven clinical trials to reduce diabetes complications
- Investigator-driven clinical trials on off-patent medicines for children

4th Key Research Challenge: How lifestyle affects health and how this can be mitigated



FFG

- **Brain-related diseases, including lifestyle-related health issues:** addiction, other mental health issues not yet covered by the previous calls such as compulsive disorders in children
- **Lifestyle determinants: diabetes, obesity and cardiovascular diseases**
- **Social determinants of health, e.g. health inequalities**

Seite 27

5th Key Research Challenge: Global Health



FFG

- Antimicrobial resistance
- Emerging epidemics
- ...

Seite 28

5. Ausschreibung RP7 Gesundheit



- **Veröffentlichung voraus. Ende Juli 2010**
- **Verschiedene Einreichfristen:**
 - => 2 Haupt-Calls:**
 - FP7-HEALTH-2011-single-stage (22 Topics): **Herbst/Winter 2010**
 - FP7-HEALTH-2011-two-stage (27 Topics):
 - 1. Stufe ~ Oktober 2010**
 - 2. Stufe Beginn 2011**
 - => 1 Spezial-Calls**
 - FP7-ERANET-2011-RTD (2 Topics): **Winter 2010/2011**

Seite 29

1

Biotechnology, generic tools and technologies for human health

1.1 High-throughput research

Tools and technologies for high-throughput research; genome-based biomarkers; high-throughput proteomics

1.2 Detection, Diagnosis and Monitoring
closed

1.3 Suitability, safety and efficacy of therapies
closed

1.4 Innovative therapeutic approaches and interventions

Regenerative medicine clinical trials; tools and technologies and devices for regenerative medicine; high-affinity protein scaffolds for therapeutic use; High impact project for better immunisation; chronic inflammatory and autoimmune diseases

DRAFT

Seite 30

2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES: LARGE SCALE DATA GATHERING, SYSTEMS BIOLOGY

2.1.1 Large Scale data gathering

High impact initiative on the human epigenome; proteins and interactions in health and disease; host determinants of infectious diseases...

2.1.2 *Systems biology*

closed

DRAFT

2.2. RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN DEVELOPMENT AND AGEING

2.2.1 Brain and related diseases

Childhood-onset neurodegenerative diseases; role of neuroinflammation in neurodegen. diseases; addictive/compulsive behaviour in children and adolescents; paediatric neurodegen. disorders...

2.2.2 Human development and ageing

Therapeutic interventions in the elderly population; linking human development and ageing

DRAFT

2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES

2.3.1 Anti-microbial drug resistance including fungal pathogens

Off-patent antibiotics; evolution and transfer of antibiotic resistance; gram negative multi-drug resistant infections; multi-analyte diagnostic tests; microbial biofilms

2.3.2 *HIV, AIDS, malaria and tuberculosis* closed



DRAFT

2.3.3 Potentially new and re-emerging epidemics

pathogens with zoonotic background; control of Dengue fever...

2.3.4 *Neglected infectious diseases (NID)* closed



DRAFT

2.4 TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES

2.4.1 Cancer

Treatment trials for rare Cancers; cancers with poor prognosis; infection-related cancers;

2.4.2 Cardiovascular Disease (CVD)

Clinical trials for management of CVD; biomarkers in prevention and management of CVD;

2.4.3 Diabetes and Obesity:

Clinical trials to reduce diabetes complications; novel treatment strategies based on knowledge of cellular dysfunction; effects of lifestyle factors on diabetes/obesity; genetic and environmental factors; ERA-NET

DRAFT

2.4.4 Rare diseases

closed

2.4.5 Other chronic diseases

closed

DRAFT

3.1 Translating clinical research into clinical practice including better use of medicines, and appropriate use of behavioural and organisational interventions and health therapies and technologies

closed

3.2 Quality, solidarity and sustainability of health systems

closed

DRAFT

Seite 37

3.3 Enhanced health promotion and disease prevention

Inequities in the determinants of health; strategies for sustainable behaviour change; transfer of research into policy in the fields of health promotion and disease prevention; road-map for mental health research in Europe

3.4 International Public Health & Health Systems

Improve reproductive health and health inequity; sustainable capacity for research for health in low and & middle income countries; public health and health services/cooperation between Europe, Africa, Latin America

DRAFT

Seite 38

4.1. Coordination and Support Actions across the Theme

Networking of major research institutions to coordinate communication actions; targeting publication bias; linking EU and Latin America policy making institutions; supporting actions and events related to presidency of the EU

4.2 Responding to EU Policy Needs

Clinical trials on off-patent medicines for children; adverse drug reaction research; new methodologies for clinical trials in personalised medicine

DRAFT

Projektantrag - Übersicht



- **Ausarbeitung des Projektantrages**
 - « Guide for Applicants »
 - Part A (Formulare)
 - Part B (Text)
 - Beschreibung des Projektes – ca. 80 Seiten
 - 1. Scientific and/or technical quality, relevant to the topics addressed by the call
 - 2. Implementation
 - 3. Impact
- **Einreichung des Antrages**
 - Online, via EPSS – Electronic Proposal Submission Service: <https://www.epss-fp7.org/epss/>

Zweistufige Einreichung



First stage:

- proposal size limited to 6 pages
(5 pages max. on proposed research and expected impact
+1 page max. to describe consortium & financial resources)
- only the coordinator needs to complete the 'A forms'
- evaluation of 2 criteria only (S/T quality and Impact)
- Higher thresholds

Second stage:

- only coordinators of proposals passing Stage 1 will be invited to submit full proposals for Stage 2
- evaluation on all 3 criteria, independently from Stage 1
- Higher thresholds

Seite 41

Die Evaluierungskriterien



3 Hauptkriterien:

- 1. Wissenschaftliche/ technische Qualität**
- 2. Implementierung**
- 3. Auswirkung – Impact**

Für jedes Kriterium 0 bis 5 Punkte, halbe Punkte möglich

Threshold für jedes Kriterium = 3/5

Gesamt - Threshold = 10/15

Registrierung als Experte: <https://cordis.europa.eu/emmfp7/>

Seite 42

3 Gebiete sind ausgeschlossen von der Förderung

- Human reproductive cloning
- Intentional germ line modification*
(* Research relating to cancer of the gonads can be financed)
- Creation of human embryos for research or stem cell procurement

Key issues:

- for humans: *Informed Consent / Data Protection / Privacy*
- for animals: the 3Rs (Reduce, Replace, Refine)
- for **human embryonic stem cells**, same conditions as in FP6

Neu in RP7

- Alle Information über ethische Fragestellungen müssen im Antrag enthalten sein

Seite 43

Key factors for success in applying for FP7 funding

**Competition is tough :
only the best projects get funded**

- **the proposal must address the topic and the workprogramme** (not wishful thinking)
- **the consortium of partners must be excellent and appropriate for the tasks** (select the right partners)
- **the proposal must address all 3 criteria**
- **convince the evaluators** (don't rely on reputation)
- **and, of course, respect the basic rules** (deadlines, N° of participants, ceilings, length, ethics...)

Maximale Erstattungsquoten	F & E (einschl. relevanter Innovations- u. Koordinierungsaktivitäten)	Demonstrationsaktivitäten	Ausbildungsmaßnahmen	Management Konsortium	Andere Aktivitäten
Verbundprojekte	50 % 75 % *	50 %	100 %	100 %	100 %
Exzellenznetze	50 % 75 % *	50 %	100 %	100 %	100 %
Koordinierungs-Unterstützungsmaßnahmen	-	-	100 %	100 %	100 %

* Öffentl. Einrichtungen, Hochschulen, (non-profit) Forschungszentren, KMU

nicht rechtsverbindlich

Seite 45

Kommende Veranstaltungen

1. FFG Akademie - 2-tägige Trainings, kostenlos

- Das EU-Rahmenprogramm für F&E für Newcomer
- Projektentwicklung und Antragstellung im 7.RP
- Management von Projekten des 7. RP

Termine Antragsstellertraining – Zielgruppe KoordinatorInnen!

- 14. und 15. Juni 2010 (noch Restplätze)
- 20. und 21. September 2010 (Anmeldestart: 21.7.2010)

Infos und Anmeldung: http://rp7.ffg.at/ffg_eip_akademie

2. FFG: Call Auftaktveranstaltung: 29. Juni 2010, Wien


NCPs und ExpertInnen im EIP beraten und coachen Sie sehr gerne im gesamten Projektzyklus, von der Antragstellung bis zur Verwertung der Ergebnisse, **ABER..**



Sie suchen Unterstützung beim **Schreiben** von Anträgen ?

Trainingsprogramm für KonsulentInnen im 7. RP

- Start im Februar 2008
- Jährliche Trainings und Fachzirkel



Europäisches Forschungsrahmenprogramm

FFG

Deutsch / Englis




Home > Services der FFG > FFG Akademie / EP > KonsulentInnen zu...

KonsulentInnen zur Unterstützung Ihrer Einreichung und Projektentwicklung im 7. RP

Die hohe Kundennachfrage nach ExpertInnen, die AntragstellerInnen auch operativ beim Schreiben und Abwickeln von EU-Projekten unterstützen, war Beweggrund für die Entwicklung und Implementierung eines speziellen Trainingsprogrammes für KonsulentInnen (nähere Informationen dazu finden Sie [hier](#)).

Nachstehend finden Sie die TeilnehmerInnen des Trainingsprogrammes in alphabetischer Reihenfolge. Sie haben auch die Möglichkeit das Angebot nach spezifischen Themen zu sortieren.

- Life Sciences (inkl. Health, KBBE)
- IKT / Sicherheit
- Nanowissenschaften, Nanotechnologien, Werkstoffe und neue Produktionstechnologien
- Umwelt / Energie
- Verkehr / Weltraum
- Human- & Geisteswissenschaften

 DI Petra BUSSWALD	<ul style="list-style-type: none">• Life Sciences (inkl. Health und KBBE)• IKT / Sicherheit• Umwelt / Energie• Verkehr	akayon internet umwelt förderung Wien / Steiermark
 Ino. Maa Toni EISER	<ul style="list-style-type: none">• IKT - Mikroelektronik, Illusionstechnik• NBP• Umwelt / Energie• Verkehr / Weltraum	Innovation-Strategie-Förderung Salzburg
 Maa. Andrea FEENZ	<ul style="list-style-type: none">• IKT / Sicherheit• NBP• Umwelt / Energie• Verkehr / Weltraum• Human- und Geisteswissenschaften	Skills International GmbH Steiermark / Kosovo

http://rp7.ffg.at/ffg_eip_akademie_bd_expertisen



WICHTIG! Kosten der KonsulentInnen sind über die **Anbahnungsfinanzierung** förderbar.

Anbahnungsfinanzierung

- Finanzielle Unterstützung für die Erstellung Ihres Antrages
- Einreichung möglich ab Veröffentlichung des Calls bis spätestens 3 Wochen vor Deadline
- Kosten: Personalkosten, Reisekosten, Workshops, Beratungsleistungen Dritter....
- Förderhöhen: (Richtwerte und Obergrenzen)
 - ProjektpartnerInnen: 7.000 € (in Ausnahmefällen bis 12.000 €)
 - KoordinatorInnen: 15.000 € (in Ausnahmefällen bis 20.000 €)
- Ko-Finanzierung: max. 75% der Vorbereitungskosten
- Anbahnungsfinanzierung Wissenschaft oder Wirtschaft





Innovative Medicines Initiative (IMI):

Konzept und Ausblick auf die 3. Ausschreibung



- Worum geht es bei IMI?
- Ausblick auf die 3. IMI-Ausschreibung





Diagnose: Schwachstellen und Engpässe in der Entwicklung neuer Arzneimittel

- Hohe „**attrition rate**“: mangelnde Voraussagbarkeit der Sicherheit und Effizienz von Arzneimitteln
- Stagnation der **biomedizinischen Innovation** durch die pharmazeutische Industrie: fehlende Investments, brain drain, „fragmentierte Forschungslandschaft“

- Durch **neue Methoden** (tools, assays, screens) **bessere Vorhersagbarkeit** der Sicherheit und Effizienz von Arzneimitteln erreichen - „Modernisierung“ (kein Ziel: Entwicklung neuer Medikamente)
- **Wettbewerbsfähigkeit** Europas im Bereich der biomedizinischen Innovation steigern: höhere Standortattraktivität (industrielle F&E-Investitionen; „reversed brain-drain“)
- „Wiedererlangung“ der weltweiten Führung der europäischen pharmazeutischen Industrie




Figure 4 : Interdependencies between the Four-Pillars of the Strategic Research Agenda


Wie sollen die Ziele der IMI erreicht werden?




FFG

- Grundlage: Kooperation zwischen Europäischer Kommission und dem Europäischen Verband der Pharmazeutischen Industrien und Vereinigungen (EFPIA) -> **IMI Joint Technology Initiative (JTI)**
- **Neue Form der Zusammenarbeit** zwischen konkurrierenden pharmazeutischen Firmen sowie Universitäten, Forschungsorganisationen, kleinen oder mittleren Unternehmen (KMU), Patientenverbänden u.a.: -> „public-private partnership“

Stufe 1:





Ausblick auf die 3. IMI-Ausschreibung

Scientific Priorities 2010 veröffentlicht

Fokus: **Efficacy Pillar**



- Assessment of drug induced toxicity in relevant organs - Safety
- Immunological safety of biopharmaceuticals - Safety
- Assessment of Inflammatory disease - Efficacy
- Improve infrastructure for Tuberculosis medicine - Efficacy
- Enhancing translation in neurological disease - Efficacy
- Personalised medicine approaches in diabetes – Efficacy
- Fostering broader understanding of pharmaceutical R&D in the broader public - Education and Training

Call-Eröffnung: letztes Quartal 2010

Ausblick auf die 3. IMI-Ausschreibung



FFG

A) Assessment of drug induced toxicity in relevant organs – Surrogates for early drug failure

Problem: Lack of sensitive and highly predictive test systems for assessment of drug induced toxicity in organs like liver, cardiovasc. System, testes.

Objectives: Knowledge Management, improve mechanistic understanding; novel biomarkers, tools and assays, validation principles for models,...

B) Immunological safety of Biopharmaceuticals

Problem: Evaluation of safety of monoclonal antibodies, vaccines, interferons etc → immunotoxic effects, difficult to predict; no guidelines

Objectives: Define key proteins of immunogenicity of biopharmaceuticals, consistent assays, predictive animal models; Knowledge Management,...

Ausblick auf die 3. IMI-Ausschreibung



FFG

C) Assessment of Inflammatory Diseases

Problem: Lack of validated/accepted measurements to be used as intermediates in interventions studies → disease manifestation, more homogeneous subgroups of patients; pre-clinical models lack key features of human disease,...

Objectives: Identification/validation of new models, candidate biomarkers for diagnosis, prognosis, efficacy; predictors to support patient stratification

D) Improve scientific and pre-clinical models and tools for Tuberculosis research

Problem: Current TB therapies > 40 years old; scientific and clinical infrastructure needs to be improved

Objectives: New pre-clinical models, translatable biomarkers, mathematical models, standardized technology/protocols

Ausblick auf die 3. IMI-Ausschreibung



E) Enhancing translation in neurological disease

Problem: Complexity of diseases, lack of translatable animal models and standardised clinically validated tools for assessing disease progression, drug response and patient stratification

Objectives: relevant animal models, assays, biomarkers -> better understanding of pathological processes; confirm defined translational endpoints; network of European clinical sites,...

F) Development of personalized medicine approaches in diabetes

Problem: No individualized treatments yet; limited number of compounds, patient sub-populations not well defined

Objectives: databases, clinical studies to identify genotypes and phenotypes of patients; identify low frequency gene variants with high indiv. Impact, new molec. Targets, biomarkers; better understanding of new cell and animal models,...

Partner Search platform for IMI



The screenshot shows the homepage of the IMI Partnering Platform. At the top, there is a header with the Federal Ministry of Education and Research logo, the text 'INNOVATIVE MEDICINES INITIATIVE', and the NKS logo. Below the header is a navigation menu with buttons for Home, Call 2009, Partner search, Documents, Links, Contact, Imprint and Privacy, and Register here. The main content area is titled 'Welcome to the IMI Partnering Platform' and contains several sections: 'Registration' (explaining the benefits of registering), 'Call 2009' (providing access to information for the upcoming call), 'Partner Search' (describing the search functionality), 'Matchmaking & Alert' (explaining the alert system), and 'My profile' (describing the profile management options). On the right side, there is a 'News / Upcoming Events' section with two entries: '1st Call 2008' (IMI JU has received 18 proposals) and '2nd IMI Call 2009' (IMI announced on September 14th). At the bottom right, there is a 'User login' section with a 'Username:' field and a password field.

www.imi-partnering.eu

IMI- Webseiten:

FFG-Homepage: http://rp7.ffg.at/health_jti_imi

IMI-website: www.imi.europa.eu

Beratung und Kontakt: ylva.huber@ffg.at

Tel: +43 5 77 55 4102

A large, stylized graphic featuring a red and white splash or cluster of dots, similar to the FFG logo, positioned above the text 'VIEL ERFOLG !!!'. The text is written in a bold, red, sans-serif font on a white, slightly tilted rectangular background. The background of the entire page is light gray with faint, abstract shapes.

Kontakt:

Dr. Astrid Hoebertz
astrid.hoebertz@ffg.at
05 / 7755-4104

Dr. Ylva Huber
ylva.huber@ffg.at
057755-4102